Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • Data Privacy
  • Français
  • my CNW 
    • Login
    • Register
  • Client Login 
    • Online Member Centre
    • Next Gen Communications Cloud
    • Cision Communications Cloud®
  • Sign Up
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
Advanced Search
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Canadian Federal Government
      • Canadian Municipal Government
      • Canadian Provincial Government
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

  • Advanced Search
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Hamburger menu
  • Cision Canada
  • Send a Release
  • FR
    • Phone

    • 877-269-7890 from 8 AM - 10 PM ET

    • ALL CONTACT INFO
    • Contact Cision

      877-269-7890
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Overview
  • Cision Communications Cloud®
  • Monitoring
  • Distribution
  • Multimedia
  • Guaranteed Paid Placement
  • AI Tools
  • IR
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media
  • Send a Release
  • Sign Up
  • Resources
  • Blog
  • Journalists
  • Webcasts
  • GDPR

Janssen Inc. Receives Health Canada Approval of DARZALEX® (daratumumab) by Priority Review for Patients with Multiple Myeloma Who Have Had At Least One Prior Therapy Français


News provided by

Janssen Inc.

Apr 17, 2017, 07:30 ET

Share this article

Share toX

Share this article

Share toX

DARZALEX® combination therapy significantly improved progression-free survival (PFS) compared to standard of care regimens alone

TORONTO, April 17, 2017 /CNW/ - Janssen Inc. announced today that Health Canada has approved DARZALEX® (daratumumab), in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.1 Due to the high unmet medical need for multiple myeloma patients, DARZALEX® was granted a Priority Review by Health Canada for this submission.

Multiple myeloma is an incurable blood cancer that occurs when malignant plasma cells grow uncontrollably in the bone marrow.2,3  The disease can be very complex to treat as most patients relapse or become resistant to standard therapies, making the approval of new treatment options so important.4,5  Janssen looks forward to working with insurers to determine how DARZALEX® can be made available for patients through both private and public insurance plans.

In June 2016, Health Canada issued a Notice of Compliance with Conditions (NOC/c) approving DARZALEX® for those with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are refractory to both a PI and an IMiD (meaning they didn't respond to treatment).6  With this new approval, patients can now use DARZALEX® treatment earlier in their disease. 

"Canadians living with multiple myeloma have had good reason for hope in recent years with the Health Canada approvals of new treatments like DARZALEX®," says Aldo Del Col, Co-Founder and Chairman, Myeloma Canada. "While this is encouraging, it is just a first step. There are hurdles to overcome before funding and access to these new treatments are approved by government drug plans."

Data from two Phase 3 studies supported this new approval.  They include the open-label, randomized clinical studies POLLUX (MMY3003) and CASTOR (MMY3004). POLLUX was published in The New England Journal of Medicine, with an accompanying editorial, in October 20167; and CASTOR was published in The New England Journal of Medicine in August 2016.8  

POLLUX showed that DARZALEX®, in combination with lenalidomide and dexamethasone, significantly improved progression free survival (PFS) compared to lenalidomide and dexamethasone alone.9  While the median PFS had not been reached in patients treated with DARZALEX® in combination with lenalidomide and dexamethasone, it was 18.4 months for patients treated with lenalidomide and dexamethasone alone. The PFS hazard ratio (HR) was 0.37 (99.39 per cent CI: 0.23, 0.59; p<0.0001), representing a 63 per cent reduction in the risk of disease progression or death in patients treated in the DARZALEX® arm.10  The study also showed that DARZALEX® used in combination significantly increased the overall response rate (ORR) (91 per cent vs. 75 per cent, p<0.0001), compared to lenalidomide and dexamethasone alone, also doubling rates of stringent complete response (sCR) (18 per cent vs. 7 per cent) and complete response (CR) (25 per cent vs. 12 per cent), and increasing very good partial response (VGPR) (32 per cent vs. 24 per cent).11

The second study, CASTOR, found the median PFS had not been reached in patients treated with DARZALEX® in combination with bortezomib and dexamethasone and was 7.2 months in the bortezomib and dexamethasone arm. The PFS hazard ratio (HR) was 0.39 (98.98% CI: 0.26, 0.58; p-value < 0.0001), representing a 61 per cent reduction in the risk of disease progression or death for patients in the DARZALEX® arm.12  DARZALEX® used in combination was also shown to significantly increase ORR (79 per cent vs. 60 per cent, p<0.0001), compared to bortezomib and dexamethasone alone, also doubling rates of sCR (4 per cent vs. 2 per cent), CR (14 per cent vs. 7 per cent), and VGPR (38 per cent vs. 19 per cent).13

"Having more options in the treatment of multiple myeloma is incredibly important," says Dr. Michael Sebag, Hematologist at the McGill University Health Centre.* "Not only can DARZALEX®  be used as a single agent, but clinical data now show significant efficacy in improved progression-free survival when it is used in combination with two of the most widely used treatment classes. This makes it a versatile option for patients who have received at least one prior therapy."

In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize DARZALEX®.14

About Multiple Myeloma
Multiple myeloma is the most common plasma cell cancer15 and is characterized by an excess proliferation of plasma cells.16  In Canada, there were an estimated 2,700 new cases in 2016 and an estimated 1,450 deaths associated with the disease.17  While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed due to symptoms that can include bone fractures or pain, low blood counts, calcium elevation, and kidney problems.18

About DARZALEX® (daratumumab)
DARZALEX® is the first CD38-directed monoclonal antibody (mAb) to be approved to treat multiple myeloma. It binds to CD38, a surface protein highly expressed across multiple myeloma cells.19 DARZALEX® induces tumour cell death through cell lysis via multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).20  DARZALEX® has also demonstrated immunomodulatory effects such as increasing CD4+ and CD8+ T-cells counts, which may contribute to clinical response.21

Overall, the safety of the DARZALEX® combination therapy was consistent with the known safety profiles of DARZALEX® monotherapy (D) and lenalidomide plus dexamethasone (Rd), respectively. In data from the POLLUX trial, the most frequent (≥20 per cent) treatment-emergent adverse events (TEAEs) [DRd/Rd] were infusion reactions (48 per cent/0 per cent), diarrhea (47 per cent/28 per cent), nausea (25 per cent/16 per cent), fatigue (35 per cent/29 per cent), pyrexia (21 per cent/11 per cent), upper respiratory tract infection (69 per cent/52 per cent), muscle spasms (27 per cent/20 per cent), cough (32 per cent/15 per cent), dyspnea (23 per cent/14 per cent), constipation (30 per cent/26 per cent), anemia (34 per cent/36 per cent), neutropenia (60 per cent/44 per cent) and thrombocytopenia (28 per cent/30 per cent).22

In data from the CASTOR study, the safety of the DARZALEX® combination therapy was consistent with the known safety profiles of DARZALEX® monotherapy (D) and bortezomib plus dexamethasone (Vd), respectively. The most frequent TEAEs [DVd/Vd] (>20 per cent) were infusion reactions (45 per cent/0 per cent), diarrhea (34 per cent/22 per cent), peripheral edema (24 per cent/14 per cent), upper respiratory tract infection (49 per cent/31 per cent), peripheral sensory neuropathy (49 per cent/38 per cent), cough (30 per cent/14 per cent), dyspnea (21 per cent/11 per cent), thrombocytopenia (60 per cent/44 per cent), anemia (28 per cent/32 per cent) and fatigue (22 per cent/25 per cent).23                                                                                             

More information about DARZALEX® is available at www.janssen.com/canada.

About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease.  Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com/canada. Follow us on Twitter at @JanssenCanada.

*Dr. Michael Sebag was not compensated for any media work. He has been a paid consultant to Janssen Inc.

References:
______________________________
1 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
2 Kumar, SK et al. Leukemia. 2012 Jan; 26(1):149-57.
3 American Cancer Society. "Multiple Myeloma Overview." Available at:http://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-what-is-multiple-myeloma. Accessed November 2015.
4 Kumar, SK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.
5 Turesson, I et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28: 830–34.
6 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
7 Dimopoulos, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375:1319-1331.
8 Palumbo, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med 2016; 375:754-766.
9 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
10 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
11 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
12 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
13 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
14 Janssen Biotech, Inc. "Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab." Issued August 30, 2012.
15 Canadian Cancer Society. "Types of Multiple Myeloma," Available at: http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/multiple-myeloma/types-of-multiple-myeloma/?region=on. Accessed September 2015.
16 American Cancer Society. "Multiple Myeloma Overview" http://www.cancer.net/cancer-types/multiple-myeloma/overview. Accessed June 2015.
17 Canadian Cancer Society. "Canadian Cancer Statistics 2016." Available at https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2016-EN.pdf?la=en. Accessed March 2017.
18 Canadian Cancer Society. "Signs and Symptoms of Multiple Myeloma," Available at: http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/signs-and-symptoms/?region=on. Accessed September 2015.
19 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
20 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
21 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
22 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]
23 [DARZALEX™ Product Monograph, Janssen Inc., April 13, 2017]

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the efficacy and availability of DARZALEX® (daratumumab). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of obtaining funded access to DARZALEX® for patients; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

SOURCE Janssen Inc.

Janssen Inc., Jennifer McCormack, Office: (416) 382-5121; Investor Contact: Lesley Fishman, Office: (732) 524-3922

Modal title

Organization Profile

Janssen Inc.

    Also from this source

  • Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

  • Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour

  • RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer

Contact Cision

  • 866-245-2317
    from 8 AM - 10 PM ET
  • Become a Client
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • General Enquiries
  • Media

Products

  • Cision Communications Cloud®
  • Media Monitoring
  • Content Distribution
  • Multimedia Distribution
  • Measurement & Analytics
  • Investor Relations

About

  • About Cision Canada
  • About Cision
  • Media Partners
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud®
  • my CNW

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Centre
  • Next Gen Communications Cloud
  • Cision Communications Cloud
  • my CNW
877-269-7890
from 8 AM - 10 PM ET
  • Terms of Use
  • Information Security Policy
  • Site Map
  • Cookie Settings
  • Accessibility Statement
Copyright © 2025 CNW Group Ltd. All Rights Reserved. A Cision company.